Dustin Samples

Cancer Nursing Today nonprod

Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) is a curative option for many hematologic malignancies, but it comes with significant risks, especially graft-versus-host disease (GVHD). Scientists have long aimed to balance graft-versus-tumor (GVT) and graft-versus-leukemia (GVL) effects while minimizing GVHD. Orca-T, a precision cell therapy, combines stem and immune cells, utilizing purified donor regulatory T cells to control harmful immune responses.A study presented at the 11th Annual Meeting of the Society of Hematologic Oncology (SOHO), Houston, Texas, examined outcomes of 151 patients who received Orca-T for hematologic malignancies and had at least 100 days of follow-up. These patients were in complete remission and underwent myeloablative conditioning (MAC) followed by GVHD prophylaxis with either tacrolimus or sirolimus. Results were compared to a control group that received traditional allo-HSCT with peripheral blood stem cell (PBSC) source and tacrolimus/methotrexate prophylaxis.The cohort who received Orca-T achieved rapid engraftment and a minimal graft failure rate (1.6%) and demonstrated significantly better outcomes at 1 year, with a 70% GVHD-free, relapse-free survival (GRFS) rate and an 88% overall survival (OS) rate compared to the control cohort&rsquo;s 21% GRFS and 68% OS. In addition, non-relapse mortality (NRM) was lower with Orca-T (4%) compared to the control group (10%) at 1 year.Patients who received a specific conditioning regimen of busulfan, fludarabine, and thiotepa with Orca-T showed exceptional outcomes, including an 87% relapse-free survival (RFS) rate and no NRM at 1 year. Severe acute GVHD and moderate-to-severe chronic GVHD rates were low, with an 81% GRFS and 94% OS at 1 year.Orca-T demonstrated robust GVT and GVL effects while successfully reducing GVHD and non-relapse mortality, even when combined with myeloablative conditioning. These findings suggest that Orca-T can potentially enhance outcomes in allo-HSCT. A phase 3 clinical trial is currently underway to further evaluate its efficacy compared to standard treatment.ReferenceSalhotra A, Oliai C, Hoeg RT, et al. Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease (GvHD) and Toxicity. Abstract AML-643. Presented at the 11th Annual Meeting of the Society of Hematologic Oncology; September 6-9, 2023; Houston, Texas.

Orca-T Improves GVHD-Free, Relapse-Free Survival Outcomes Better Than Standard Treatment

Conferences

Results were further improved when Orca-T was given in combination with a regimen of busulfan, fludarabine, and thiotepa.

About Us

Editorial Policy

Authors

Advertising

eNewsletters

Contact Us

Contribute

Calendar of Events

Career Center

Blood Cancers Today

GU Oncology Now

DocWire News

MashupMD

Urban Health Today

Breast Cancer

Colorectal Cancer

GI Cancer

GU Cancer

Gynecologic Cancer Awareness Month

Gyn-Onc

Blood Cancer Awareness Month

GVHD

Leukemia

Lymphoma

Myeloproliferative Neoplasms

Multiple Myeloma

Myelodysplastic Syndrome

Myelofibrosis

Sickle Cell

Hem/Onc

Professional Development

Patient Voice

Lung Cancer

Skin Cancer

Other Tumor Types

News

Treatment

More

Calendar

CARE Award

Best Practices

Expert Interviews

Subscribe